These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

64 related articles for article (PubMed ID: 2657275)

  • 21. Transdermal clonidine therapy in elderly mild hypertensives: effects on blood pressure, plasma norepinephrine and fasting plasma glucose.
    Klein C; Morton N; Kelley S; Metz S
    J Hypertens Suppl; 1985 Dec; 3(4):S81-4. PubMed ID: 3868715
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evaluation of safety and efficacy of transdermal therapeutic system-fentanyl in adult patients with gynecological cancer-related pain.
    Lorvidhaya V; Katanyoo K; Srisomboon J; Suprapaphorn P; Cheewakriangkrai C
    J Med Assoc Thai; 2004 Mar; 87(3):319-25. PubMed ID: 15117050
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Catapres-TTS: a two year posttrial followup.
    Kellaway GS; Lubbe WF
    N Z Med J; 1988 Jun; 101(847 Pt 1):380. PubMed ID: 2970607
    [No Abstract]   [Full Text] [Related]  

  • 24. One year efficacy and tolerability of clonidine administered by the transdermal route in patients with mild to moderate essential hypertension--a multicentre open label study. The Antihypertensive Patch Italian Study (APIS) Investigators.
    Clin Auton Res; 1993 Dec; 3(6):379-83. PubMed ID: 8193525
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of transdermal clonidine treatment on withdrawal symptoms associated with smoking cessation. A randomized, controlled trial.
    Ornish SA; Zisook S; McAdams LA
    Arch Intern Med; 1988 Sep; 148(9):2027-31. PubMed ID: 3046542
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical pharmacokinetic and pharmacodynamic evaluation of transdermal drug delivery systems of salbutamol sulfate.
    Narasimha Murthy S; Hiremath SR
    Int J Pharm; 2004 Dec; 287(1-2):47-53. PubMed ID: 15541911
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of PEG6000 on the in vitro and in vivo transdermal permeation of ondansetron hydrochloride from EVA1802 membranes.
    Krishnaiah YS; Rama B; Raghumurthy V; Ramanamurthy KV; Satyanarayana V
    Pharm Dev Technol; 2009; 14(1):50-61. PubMed ID: 18819031
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Pharmacokinetics and efficacy of phenazepam after transdermal and enteral administration in rats].
    Zherdev VP; Voronina TA; Garibova TL; Kolyvanov GB; Litvin AA; Sariev AK; Tokhmakhchi VN; Vasil'ev AE
    Eksp Klin Farmakol; 2003; 66(1):50-3. PubMed ID: 12683082
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy of clonidine as transdermal therapeutic system: the international clinical trial experience.
    Lowenthal DT; Saris S; Paran E; Cristal N; Sharif K; Bies C; Fagan T
    Am Heart J; 1986 Oct; 112(4):893-900. PubMed ID: 3532747
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Determination of the release of drugs from transdermal therapeutic systems. Presentation of a new release system].
    Chen LS; Ebel S; Hoffmann U; Osterwald HP
    Arzneimittelforschung; 1989 Nov; 39(11A):1494-7. PubMed ID: 2624596
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Transdermal delivery system for zidovudine: in vitro, ex vivo and in vivo evaluation.
    Narishetty ST; Panchagnula R
    Biopharm Drug Dispos; 2004 Jan; 25(1):9-20. PubMed ID: 14716748
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [The bioavailability of transdermal therapeutic system of timolol].
    Ji XF; Ping QN; Liu GJ; Yu ST
    Yao Xue Xue Bao; 1993; 28(8):609-13. PubMed ID: 8285070
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Postoperative analgesia using a low-dose, oral-transdermal clonidine combination: lack of clinical efficacy.
    Owen MD; Fibuch EE; McQuillan R; Millington WR
    J Clin Anesth; 1997 Feb; 9(1):8-14. PubMed ID: 9051539
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dose linearity of clonidine after transdermal application.
    Wallenstein G; Gladigau V
    Clin Auton Res; 1993 Dec; 3(6):369-72. PubMed ID: 8193523
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Transdermal clonidine application: long-term results in essential hypertension.
    Groth H; Vetter H; Knüsel J; Foerster E; Siegenthaler W; Vetter W
    Klin Wochenschr; 1984 Oct; 62(19):925-30. PubMed ID: 6503214
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Carrier-mediated transport of clonidine in human keratinocytes.
    Grafe F; Wohlrab W; Neubert R; Brandsch M
    Eur J Pharm Sci; 2004 Feb; 21(2-3):309-12. PubMed ID: 14757503
    [TBL] [Abstract][Full Text] [Related]  

  • 37. In vitro release profiles of clonidine transdermal therapeutic systems and scopolamine transdermal patches.
    Shah VP; Tymes NW; Skelly JP
    Pharm Res; 1989 Apr; 6(4):346-51. PubMed ID: 2748524
    [No Abstract]   [Full Text] [Related]  

  • 38. Programmable transdermal clonidine delivery through voltage-gated carbon nanotube membranes.
    Strasinger C; Paudel KS; Wu J; Hammell D; Pinninti RR; Hinds BJ; Stinchcomb A
    J Pharm Sci; 2014 Jun; 103(6):1829-38. PubMed ID: 24788096
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evaluation of substrates for 90 degrees peel adhesion--a collaborative study. II. Transdermal drug delivery systems.
    Wokovich AM; Brown SA; Shen M; Doub WH; Cai B; Sadrieh N; Chen ML; Machado S; Buhse LF
    J Biomed Mater Res B Appl Biomater; 2009 Jan; 88(1):61-5. PubMed ID: 18546200
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.